Genome-wide association studies (GWAS) have transformed our understanding of glioma susceptibility, but individual studies have had limited power to identify risk loci. We have performed a meta-analysis of these GWAS, a new GWAS and replication comprising 12,496 cases and 18,190 controls. We identified new loci for glioblastoma (GBM) at 1p31.3 (rs12752552; P=2.04×10 -9 , odds ratio (OR)=1.22), 11q14.1 (rs11233250; P=9.95×10 -10 , OR=1.24), 16p13.3 (rs2562152; P=1.93x10 -8 , OR=1.21), 16q12.1 (rs10852606; P=1.29×10 -11 , OR=1.18), 22q13.1 (rs2235573; P=1.76×10 -10 , OR=1.15) and for non-GBM at 1q32.1 (rs4252707; P=3.34×10 -9 , OR=1.19), 1q44 (rs12076373; P=2.63×10 -10 , OR=1.23), 2q33.3 (rs7572263; P=2.18×10 -10 , OR=1.20), 3p14.1 (rs11706832; P=7.66×10 -9 , OR=1.15), 10q24.33 (rs11598018; P=3.39×10 -8 , OR=1.14), 11q21 (rs7107785; P=3.87×10 -10 , OR=1.16), 14q12 (rs10131032; P=5.07x10 -11 , OR=1.33) and 16p13.3 (rs3751667; P=2.61×10 -9 , OR=1.18) which localize in/near RAVER2, FAM181B, MPG, HEATR3, SLC16A8, MDM4, AKT3, IDH1, LRIG1, OBFC1, MAML2, AKAP6, and LMF1 respectively. These data substantiate genetic susceptibility to GBM and non-GBM being highly distinct, likely reflecting different etiology.
Genome-wide association studies (GWAS
Glioma accounts for around 27% of all primary brain tumors and is responsible for around 13,000 cancer-related deaths in the US each year 1,2 . Gliomas can be broadly classified into glioblastoma (GBM) and lower-grade non-GBM 3 . Gliomas typically have a poor prognosis irrespective of medical care, with the most common form, GBM, having a median overall survival of only 12-14 months 1 .
So far no environmental exposures have robustly been linked to risk of developing glioma except for ionizing radiation, which accounts for a small proportion of cases 4 . Evidence for inherited predisposition to glioma is provided by a number of rare inherited cancer syndromes, such as Turcot's and Li-Fraumeni syndromes, and neurofibromatosis. Even collectively, however these account for little of the two-fold familial risk of glioma 5 . Our understanding of the heritability of glioma has been transformed by recent genome-wide association studies (GWAS), which have identified single nucleotide polymorphisms (SNPs) at 13 loci influencing risk [6] [7] [8] [9] [10] [11] [12] .
Due to limited statistical power of the previous individual studies for additional discovery of novel glioma risk loci 13 , we performed a meta-analysis to gain a comprehensive insight to glioma etiology of these previously published GWAS and a new GWAS with replication comprising 12,496 cases and 18,190 controls, identifying 13 new risk loci.
We initially analysed GWAS SNP data passing quality control for 10,977 cases (5,665 GBM, 4,827 non-GBM) and 17,386 controls from seven studies of European ancestry: a new GWAS performed by the Glioma International Case Control Consortium (GICC) (Supplementary Table 1 ) and six previously reported GWAS 8, 9, 14 . To increase genomic resolution, we imputed >10 million SNPs using the 1000 Genomes Project 15 combined with UK10K 16 as reference. Quantile-Quantile (Q-Q) plots for SNPs with minor allele frequency (MAF) >5% post imputation did not show evidence of substantive over-dispersion (λ = 1.00-1.09; Supplementary Fig. 1 ). We derived joint odds ratios (ORs) and 95% confidence intervals (CIs) under a fixed-effects model for each SNP with MAF >0.01 and associated per allele principle component (PCA) corrected P-values for all glioma, GBM and non-GBM.
We sought validation of SNP P-values from the meta-analysis at <10 -6 using in-silico replication in an additional 1,519 cases (526 GBM, 992 non-GBM) and 804 controls. In the combined meta-analysis, associations at the previously reported risk loci for all glioma at 17p13.1 (TP53), GBM at 5p15.33 Supplementary Fig. 2 ). Associations at the previously reported 3q26.2 (TERC) 10 and 12q23.33 (POLR3B) 9 loci for GBM did not attain statistical significance (respective P-values for the most associated SNPs = 2.25x10 -6 and 1.60x10 -5 ; Supplementary Table   2) .
After meta-analysis of the discovery and replication samples, we identified genome-wide significant associations marking novel loci ( Table 1, Fig. 2, Fig.3 -9 , OR=1.18). We also identified a promising association at 9q21.13 for GBM (rs34718722; P=7.77x10 -8 ). Conditional analysis confirmed the existence of two independent association signals at 7p11.2 (EGFR) defined by SNPs rs75061358 and rs723527 previously reported 6 but did not provide evidence for additional signals at any of the other established identified risk loci or the 13 newly identified loci. Collectively our findings provide strong evidence for subtype associations for glioma consistent with their distinctive molecular profiles presumably resulting from different etiological pathways (Fig. 4) .
Across the new and known risk loci, we confirmed a significant enrichment of the enhancer associated histone marks, including H3K4me1, H3K4me4, and H3K27ac in neural-progenitor cells (P<1x10 -4 ). These observations support the assertion that the GWAS loci influence glioma risk through effects on neural cis-regulatory networks, and are strongly involved in transcriptional initiation and enhancement. To gain further insight into the biological basis for associations at the 13 new risk loci we performed an expression quantitative trait loci (eQTL) analysis using RNA-Seq data on glioma from The Cancer Genome Atlas (TCGA) and normal human brain using the GTEx portal. We examined for an association between SNP genotype and expression of genes mapping Additionally for each of the risk SNPs at the 13 new loci (as well as correlated variants, r 2 >0.8) we examined published data 17, 18 and made use of the online resources, HaploRegv3, RegulomeDB, and SeattleSeq for evidence of functional effect (Supplementary Table 3 ).
The 1q32.1 association marked by rs4252707 (Fig. 2) maps to intron eight of the gene encoding MDM4 (mouse double minute 4 homolog) a p53-binding protein. Over-expression of MDM4 is a feature in TP53-mutation and MDM2-amplification negative glioma, consistent with MDM4 amplification being a mechanism by which the p53-dependent growth control is inactivated 19 . The 1q44 association marked by rs12076373 maps intronic to AKT3 (v-akt murine thymoma viral oncogene homolog 3) one of the major downstream effectors of phosphatidylinositol 3-kinase which is highly expressed during active neurogenesis, with haploinsufficiency causing postnatal microcephaly and agenesis of the corpus callosum 20 . Importantly AKT3 is hyper-expressed in glioma playing an important role in tumor viability by activating DNA repair 21 . The 3p14.1 association marked by rs11706832 localizes to intron 2 of LRIG1 (leucine-rich repeats-and immunoglobulin-like domains-containing protein 1). LRIG1 is highly expressed in the brain and is a pan-negative regulator of the EGFR signaling pathway which inhibits hypoxia-induced vasculogenic mimicry via EGFR/PI3K/AKT pathway suppression and epithelial-to-mesenchymal transition 22 . Reduced LRIG1 expression is linked tumor aggressiveness, temozolomide-resistance and radio-resistance 23, 24 . While we have previously shown an association for glioma at EGFR (7p11.2) 6 , which is well established to be pivotal in both initiation of primary GBM and progression of lower-grade glioma to grade IV we now suggest a more extensive pathway involving variation in LRIG1 and AKT3.
Of particular interest is rs7572263 mapping to 2q33.3 which localises ~50 kb telomeric to the gene encoding IDH1 (isocitrate dehydrogenase 1). Mutation of IDH1 is a driver for gliomagenesis 25, 26 and is responsible for the CpG island methylator (G-CIMP) phenotype 27, 28 . Since IDH mutation predominates in non-GBM glioma 29, 30 the association at 2q33.3 is entirely plausible as a basis for susceptibility to non-GBM glioma.
Maintenance of telomeres is central to cell immortalization and plays a central role in gliomagenesis 31 . We have previously shown the risk of GBM is strongly linked to genetic variation in the telomere-related genes TERT (5p15.33) and RTEL1 (20q13.33), but probably also TERC (3q26.2) 7, 8, 10 . To fully decipher the biological impact of these SNP associations on the glioma development require additional functional analyses. The glioma risk alleles at TERT, RTEL1, TERC and OBFC1 are however associated with increased leukocyte telomere length thereby providing a direct relationship between genotype and biology [31] [32] [33] .
The 10q24.33 association marked by rs11598018 lies intronic to OBFC1
(oligonucleotide/oligosaccharide-binding fold-containing protein 1), which functions in a telomereassociated complex protecting telomeres independently of POT1. The CST complex encoded by OBFC1, CTC1, and TEN1 competes with shelterin for telomeric DNA inhibiting telomerase-based telomere extension. The significant association between risk of non-GBM and OBFC1 variation is particularly intriguing in light of a recent report demonstrating that germline loss-of-function mutations in shelterin-complex genes are a rare cause of familial oligodendroglioma 34 .
Deregulation of pathways involved in telomere length and EGFR signalling are thus consistent with glioma risk being governed by pathways important in the longevity of glial cells and substantiate early observations that genetic susceptibility to GBM and non-GBM is highly distinct, presumably reflecting different aetiologies between GBM and non-GBM tumors (Fig. 4) . 8 The other associations we identified mark genes with varying degrees of plausibility for having a role in glioma oncogenesis. The GBM association at 16p13.33 marked by rs2562152 localizes 3 kb telomeric to MPG; a N-methylpurine DNA glycosylase that removes a diverse group of damaged bases from DNA including cytotoxic and mutagenic alkylation adducts of purines. MPG expression is linked to temozolomide resistance 35 . The association at 1p31.3 implicates Raver2; a modulator of the splicing repressor PTB (Polypyrimidine Tract Binding Protein) that is highly expressed during neurogenesis. However the region of LD encompassing rs12752552 also contains JAK1. Since the JAK1-STAT6 signaling is increasing being recognized to be relevant to glioma progression it remains to be established which gene is the functional basis for the 1p31.3 association. Similarly, the genetic and functional basis for associations at 11q14.1 (GBM), 16q12.1 (HEATR3; GBM), 22q13.1 (SLC16A8; GBM), 11q21 (MAML2; non-GBM), 14q12 (AKAP6; non-GBM), and 16p13.3 (LMF1; non-GBM)
remain to be established. However, the observation that rs10852606 variation at 16q12.1 has previously been associated with risk of both testicular (rs8046148) and esophageal (rs4785204) cancer (pairwise r 2 and D' with rs10852606, 0.67, 1.0 and 0.16, 1.0 respectively) is compatible with this locus having pleiotropic effects on tumor risk.
In conclusion we have performed the largest glioma GWAS to date identifying 13 new glioma risk loci taking the total count to 26. Our findings provide further evidence for a polygenic basis of genetic susceptibility to glioma however, and it is important to understand the biology behind these risk variants. Currently identified risk SNPs for glioma account for at best around 27% and 34% of the familial risk of GBM and non-GBM tumours respectively (Supplementary Table 4 ).therefore further GWAS-based studies in concert with functional analyses should lead to additional insights into the biology and etiological basis of the different glioma histologies. Importantly, such information can inform gene discovery initiatives and thus have a measurable impact on the successful development of new therapeutic agents. UK10K data generation and access was organised by the UK10K consortium and funded by the Wellcome Trust. The results here are in part based upon data generated by the TCGA Research Network: http://cancergenome.nih.gov/.
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METHODS
Ethics
Primary GWAS
Studies participating in GICC are described in Amirian et al. 36 and in Supplementary Table 1 , and comprise 5,189 glioma cases and 3,827 controls ascertained through centers in the US, Denmark, Sweden and the UK. Cases had newly diagnosed glioma and controls had no personal history of cancer at ascertainment. Detailed information regarding recruitment protocol is given in Amirian et al. 36 . Cases and controls were genotyped using the Illumina Oncoarray according to the manufacturer's recommendations (Illumina Inc.). Individuals with call rate <99% as well as all individuals evaluated to be of non-European ancestry (<80% estimated European ancestry using the FastPop procedure developed by the GAMEON consortium HapMap version 2 CEU, JPT/CHB and YRI populations as a reference, Supplementary Fig. 3 were excluded. For apparent first-degree relative pairs, we removed the control from a case-control pair; otherwise, we excluded the individual with the lower call rate. SNPs with a call rate <95% were excluded as were those with a MAF<0.01 or displaying significant deviation from Hardy-Weinberg equilibrium (HWE) (i.e. P<10 -5 ).
Published GWAS
We used GWAS data previously generated on four non-overlapping case-control series of Northern European ancestry, which have been the subject of previous studies; Briefly: (1) The UK-GWAS 6, 7, 9 was based on 636 cases (401 males; mean age 46 years) ascertained through the INTERPHONE study 37 . Individuals from the 1958 Birth Cohort (n=2,930) served as a source of controls; (2) 39 ; POPGEN (Population Genetic Cohort; n=678) 40 and from the Heinz Nixdorf
Recall study (n=380) 41 . Standard, quality control measures were applied to the UK, French and GliomaScan GWAS 14 -in addition to the published analysis we excluded samples from the ATBC (Finnish study) and controls from NSHDS which were excluded due to exhibiting outlying population ancestry after manual inspection of PCA plots. In total 1,653 cases and 2,725 controls were used in the current study.
GWAS imputation
GWAS data were imputed to >10 million SNPs with IMPUTE2 v2.3 46 software using a merged reference panel consisting of data from 1000 Genomes Project (phase 1 integrated release 3, March 2012) 15 and UK10K (ALSAPAC, EGAS00001000090 / EGAD00001000195 and TwinsUK EGAS00001000108/EGAS00001000194 studies). Genotypes were aligned to the positive strand in both imputation and genotyping. Imputation was conducted separately for each study, and in each, the data were pruned to a common set of SNPs between cases and controls before imputation. We set thresholds for imputation quality to retain potential risk variants with MAF>0.005. Poorly imputed SNPs defined by an information measure <0.80 with IMPUTE2 were excluded. Test of association between imputed SNPs and glioma was performed using logistic regression under an additive genetic model in SNPTESTv2.5 47 . The adequacy of the case-control matching and possibility of differential genotyping of cases and controls were formally evaluated using Q-Q plots of test statistics ( Supplementary Fig.1 ). The inflation factor λ was based on the 90% least-significant SNPs.
Where appropriate, principle components, generated using common SNPs, were included in the analysis to limit the effects of cryptic population stratification that otherwise might cause inflation of test statistics. Principle components, based on genotyped SNPs were generated for GICC, GliomaScan, MDA-GWAS and SFAGS using PLINK 48 . Eigenvectors for the German GWAS dataset was inferred using smartpca (part of EIGENSOFTv2.4) 49, 50 by merging cases and controls with Phase II HapMap samples 9 .
In silico replication
For replication of promising associations we analysed Mayo case-control and UCSF case-control and Mayo Clinic Biobank control data. The Mayo Clinic case-control study has been described previously 8, 30, 51 . Briefly, adult cases (>18 years of age) were identified at diagnosis (diagnosed at Quality control analyses were performed on each cohort separately (Mayo cases; UCSF cases; Mayo Clinic Biobank controls). SNPs with call rates <95% were removed, followed by removal of subjects with call rates <95%. Concordance of replicate samples was assessed and the sample with the higher call rate was retained. Subject's sex was verified using the sex check option in PLINK. Relationship checking was performed by estimating the proportion of alleles shared identical by descent (IBD)
for all pairs of subjects in PLINK 48 . STRUCTURE 52 was used to assess population admixture with 1000
Genomes as reference. Subjects indicated to be non-Caucasian were excluded. Prior to imputation, SNPs were tested for HWE and SNPs with HWE P<10 -6 removed. Mayo Clinic, UCSF and Mayo Clinic Biobank SNP data were each phased and imputed using the Michigan Imputation Server with the Haplotype Reference Consortium (release 1; http://www.haplotype-reference-consortium.org) as reference. Genotypes were forward-strand aligned to the 1000 genome reference and for ambiguous SNPs the Browning strand checking utility was used (http://faculty.washington.edu/sguy/beagle/strand_switching/strand_switching.html). PCA was used to correct for population stratification. The first three principal components were significantly (P<0.05) associated with case-control status. An additive logistic regression model was used to assess the association between each SNP and disease status, with genotype coded as 0, 1, or 2 copies of the minor allele, adjusted for age, sex, and the first three principal components.
Meta-analysis
Meta-analyses were performed using the fixed-effects inverse-variance method based on the β estimates and standard errors from each study using META v1.6 53 . Cochran's Q-statistic to test for heterogeneity and the I 2 statistic to quantify the proportion of the total variation due to heterogeneity were calculated 54 . Using the meta-analysis summary statistics and LD correlations from a reference panel of 1000 Genomes Project combined with UK10K we used GCTA 55, 56 to perform conditional association analysis. Association statistics were calculated for all SNPs conditioning on the top SNP in each loci showing genome-wide significance. This is carried out in a step-wise fashion.
ENCODE and chromatin state dynamics
Risk SNPs and their proxies (i.e., r 2 > 0.8 in the 1000 Genomes EUR reference panel) were annotated for putative functional effect using HaploReg v4 57 , RegulomeDB 58 and SeattleSeq Annotation 59 .
These servers make use of data from ENCODE, genomic evolutionary rate profiling (GERP) conservation metrics, combined annotation dependent depletion (CADD) scores and 60 .
Expression quantitative trait loci analysis
To examine the relationship between SNP genotype and gene expression, we made use of RNA sequence data for 389 low-grade and 138 GBM tumors of European ancestry from TCGA (accession number phs000178.v9.p8). Sequence reads from downloaded FASTQ files were aligned to the human hg19 reference genome and GRCh37 Ensembl transcriptome using TopHat v2.0.7 and Bowtie v2.0.6. Read counts per gene were generated for 62,069 Ensembl genes using featureCounts 61 as part of the Rsubread Bioconductor package 62 . For TCGA samples, European ancestry was assessed through visualization of clustering with CEU samples after principal components analysis. Untyped genotypes were imputed from Affymetrix 6 array data using similar methods to those discussed previously. Genotypes with probability >0.9 were taken forward for eQTL analysis. The association between SNP and gene expression was quantified using the Kruskal-Wallis trend test. We additionally queried publically available eQTL mRNA expression data from the GTEx portal (http://www.gtexportal.org).
Additional statistical and bioinformatics analysis
Estimates of individual variance in risk associated with glioma risk SNPs was carried out using the method described in Pharoah, et al., 2008 63 assuming the familial risk of glioma to be 1.77 64 .
Briefly, for a single allele (i) of frequency p, relative risk R and ln risk r, the variance (Vi) of the risk distribution due to that allele is given by:
Where E is the expected value of r given by:
For multiple risk alleles the distribution of risk in the population tends towards the normal with variance:
= ∑
The total genetic variance (V) for all susceptibility alleles has been estimated to be √1.77. Thus the fraction of the genetic risk explained by a single allele is given by:
⁄ LD metrics were calculated in vcftools v0.1.12b 65 using UK10K data and plotted using visPIG 66 . LD blocks were defined on the basis of HapMap recombination rate (cM/Mb) as defined using the 
